Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Dec 24, 2024 6:32pm
75 Views
Post# 36376935

595k/year

595k/year

That's a hefty price for the drug!

"According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 8.91x, though it currently operates at a loss. The newly approved drug is priced at $595,000 per year, which aligns with the anticipated cost for treatments targeting ultra-rare diseases. This development signifies Ionis Pharmaceuticals' first solo commercial drug launch...

The larger indication for severe hypertriglyceridemia (sHTG) is seen as the primary value driver for olezarsen, with analyst price targets ranging from $37 to $78. Results from pivotal studies for this indication are expected in the second half of 2025."

https://www.investing.com/news/analyst-ratings/ionis-shares-hold-as-piper-sandler-stays-positive-on-fda-nod-93CH-3787182

<< Previous
Bullboard Posts